Artificial Intelligence and Real World Data Speed Up Drug Development
Key points:
1. TriNetX is using real world data to reduce clinical trial enrollment time by as much as 40 percent
2. Artificial intelligence models are helping researchers simulate disease progression for smarter trial designs
Artificial intelligence is finally delivering the speed boost clinical trials have needed for decades. TriNetX, a company focused on real world evidence platforms, has been using artificial intelligence and health record data to supercharge patient recruitment and protocol design. On May 10, they reported that one major gastrointestinal study saw trial enrollment times fall by 40 percent, a huge leap in a field where every day counts. The platform works by identifying eligible patients in real time, using data from more than 150 million patient records across global healthcare networks. TriNetX’s digital waiting room matches individuals to appropriate trials and adjusts for factors like diversity and trial complexity. Their artificial intelligence algorithms can also simulate disease trajectories, allowing researchers to design smarter and more adaptive studies from the beginning. This helps prevent costly mid trial redesigns and improves trial retention. For diseases like pancreatic cancer, where timing is critical, this kind of tech could save lives. Clinical trial costs now top 2.6 billion dollars on average for a single new drug, so cutting down even a fraction of that has enormous implications. Researchers also report reduced administrative friction and fewer errors during recruitment. By making clinical trials more agile and inclusive, artificial intelligence may finally be the innovation that helps research catch up with the speed of discovery. TriNetX is proving that artificial intelligence’s value in medicine is not just theoretical, it is operational, measurable, and here now.
Image: PD
©2025 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.
